The abstract is read at the publisher; the summary is JClub's.
Communicating uncertainties about benefits and risks of new cancer drugs reduced US adults’ hypothetical decisions to take the drug by a mean 10.1 percentage points in a randomized trial.
- Why it matters: Cancer drugs are often approved using uncertain evidence, yet patients may not hear how benefits and risks are limited. This study tests whether uncertainty communication changes decision-making.
- What they did: Two online randomized clinical trials (May 9–July 26, 2025) assigned demographically diverse US adults to plain-language uncertainty statements. Trial 1 tested five uncertainty types; Trial 2 tested 1–4 uncertainties versus control, measuring hypothetical decisions and secondary outcomes.
- The result: In Trial 1 (n=6272), uncertainty information lowered hypothetical uptake by 10.1 pp (95% CI, -11.7 to -8.5; P<.001) across all uncertainty types, including -14.1 pp for unknown notice of improvement and -12.8 pp for unstudied similar race/ethnicity. In Trial 2, decisions decreased with each added uncertainty, and perceived effectiveness and trust fell, while worry did not change.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.